J B Chemicals & Pharma Share Price Target 2025, 2026, 2030, 2040, 2050

J.B. Chemicals & Pharmaceuticals is a well-known Indian medicine company. It makes many kinds of medicines like tablets, capsules, syrups, ointments, injections, herbal products, and active ingredients. The company focuses on long-term health problems such as stomach issues, heart and kidney care, pain, skin problems, and breathing problems. Its popular brands include Cilacar, Metrogyl, and Rantac. It sells its medicines in over 40 countries, including South Africa and Russia.

What is J B Chemicals & Pharmaceuticals Ltd NSE: JBCHEPHARM?

J B Chemicals & Pharmaceuticals was established in 1976 in Mumbai, Maharashtra, India by J.B. Mody. It is a well-known Indian medicine company that makes many types of products like tablets, syrups, injections, creams, capsules, and lozenges. The company sells its medicines in India and in many other countries. It focuses on simple, safe, and effective health products that are used in areas like heart care, stomach care, pain relief, and more.

J B Chemicals & Pharma Share Price Target

J B Chemicals & Pharma Share Price Target 2025

It is also called JBCPL or JB Pharma. It makes good-quality drugs and many types of medicines. In the beginning, the company focused on learning and improving how to make medicines. As the company grew, it changed its name in 1985 to J B Chemicals & Pharmaceuticals. It started as a small unit, slowly expanded across India and then into many other countries. It became an important and trusted name in the Indian pharmaceutical industry with careful planning and steady growth. In 2025, its share price target would be ₹1985, as per stock market analysts.

According to stock market analysts, its share price would be between ₹1385 to ₹1985 in 2025.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	1385	1985

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	1690	1918
February	1519	1798
March	1433	1747
April	1385	1682
May	1494	1725
June	1662	1842
July	1603	1812
August	1647	1769
September	1638	1745
October	1644	1721
November	1675	1844
December	1700	1985

J B Chemicals & Pharma Share Price Target 2026

The company increased its manufacturing strength by building many modern factories in India. It first started with small units and then set up bigger plants in places like Panoli, Ankleshwar, Daman, Thane, and Belapur. These factories helped the company make bulk drugs, APIs, and many types of finished medicines. The large plants built in the 1990s and early 2000s helped the company grow fast in both Indian and global markets. In 2026, its share price target would be ₹2545, as per stock market analysts.

According to stock market analysts, its share price would be between ₹1951 to ₹2545 in 2026.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2026	1951	2545

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	1951	2080
February	1974	2120
March	2010	2157
April	2042	2184
May	2065	2235
June	2078	2274
July	2110	2310
August	2158	2341
September	2185	2357
October	2221	2378
November	2252	2441
December	2325	2545

Share Price Target 2027

It makes a wide variety of products covering many health needs. The company first became strong in stomach care, heart care, and infection medicines. Later, it expanded into skin care, diabetes care, breathing problems, kidney care, and more. It also added herbal and Ayurvedic products to reach more people. The company makes medicines in many forms, like tablets, capsules, injections, syrups, gels, ointments, creams, and lozenges. This wide range helps the company supply hospitals, clinics, pharmacies, and buyers in other countries. In 2027, its share price target would be ₹3055, as per stock market analysts.

According to stock market analysts, its share price would be between ₹2500 to ₹3055 in 2027.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2027	2500	3055

Share Price Target 2028

It exports its products to over 30 countries, including places in Africa, Europe, Asia, and Latin America. It has strong markets in Russia and South Africa, where it has long-term partnerships. The company exports tablets, injections, APIs, and lozenges. This international reach helps the company earn money from different parts of the world and reduces its dependence on India alone. As demand for safe and affordable medicines grows, it continues to expand its global presence. In 2028, its share price target would be ₹3533, as per stock market analysts.

According to stock market analysts, its share price would be between ₹3020 to ₹3533 in 2028.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2028	3020	3533

Share Price Target 2029

The company makes sure all its factories follow strict quality rules and meet global standards. Many of its plants are approved by top international regulators, which allows the company to export to highly regulated countries. The company uses modern machines, advanced labs, and trained staff to maintain quality. It earns trust from doctors, patients, and global partners by following strong quality systems. In 2029, its share price target would be ₹3992, as per stock market analysts.

According to stock market analysts, its share price would be between ₹3489 to ₹3992 in 2029.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2029	3489	3992

J B Chemicals & Pharma share price Target 2030

The company invests in research and development to make its products better. The R&D team works on creating new medicines, improving old ones, and finding cheaper and faster ways to manufacture them. The company has also worked on new chemical entities and other innovations. Its research team supports both the Indian and global markets by developing products that match international needs. Innovation plays a big role in the company’s long-term success and helps it stay competitive in a fast-changing industry. In 2030, its share price target would be ₹4470, as per stock market analysts.

According to stock market analysts, its share price would be between ₹3958 to ₹4470 in 2030.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2030	3958	4470

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	3958	4090
February	3978	4132
March	3990	4160
April	4012	4184
May	4032	4225
June	4050	4252
July	4084	4274
August	4158	4300
September	4190	4332
October	4225	4352
November	4284	4415
December	4330	4470

Share Price Target 2040

It is known as one of India’s fast-growing medicine companies. It has strong brands, steady growth, and a growing global presence. Many of its medicines are among the top-selling products in India. The company invests in marketing, distribution, and new product launches to keep its position strong. It competes well with other Indian and international pharmaceutical companies with a mix of branded medicines, export products, and speciality items. In 2040, its share price target would be ₹7302, as per stock market analysts.

According to stock market analysts, its share price would be between ₹6808 to ₹7302 in 2040.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2040	6808	7302

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	6808	6984
February	6835	7012
March	6852	7040
April	6890	7068
May	6921	7089
June	6932	7120
July	6945	7155
August	6988	7178
September	7010	7190
October	7056	7232
November	7125	7258
December	7185	7302

Share Price Target 2050

Its business is divided into important segments like domestic branded medicines, export medicines, contract manufacturing, and API production. Branded medicines sold in India make up a major part of its revenue because many doctors trust and prescribe them. Export medicines are also a strong part of the business, especially in markets like Russia and South Africa. Contract manufacturing for global clients and making APIs adds more income. This balanced business model helps the company stay strong even when the market faces ups and downs. In 2050, its share price target would be ₹10118, as per stock market analysts.

According to stock market analysts, its share price would be between ₹9608 to ₹10118 in 2050.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2050	9608	10118

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	9608	9784
February	9651	9810
March	9678	9857
April	9690	9887
May	9754	9910
June	9784	9957
July	9812	9989
August	9852	10080
September	9874	10154
October	9932	10184
November	9985	10225
December	10157	10300

Should I buy J B Chemicals & Pharma stock?

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	1385	1985
2026	1951	2545
2027	2500	3055
2028	3020	3533
2029	3489	3992
2030	3958	4470
2040	6808	7302
2050	9608	10118

It could be a good stock to buy if you want to invest for a few years and not just for a short time. Many experts say the stock has more growth potential, and the company has been doing well with steady increases in sales and profit. It earns money from many areas like Indian medicines, exports, APIs, and making products for other companies, which keeps the business strong. But like all pharma companies, it still faces risks such as tough competition. So, if you want a stable and growing pharma company and are ready to hold the stock for 2–5 years, it could be a good option, but short-term or very careful investors should think more before buying.

J B Chemicals & Pharma earnings results

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales +	1,775	2,043	2,424	3,149	3,484	3,918	4,092
Expenses +	1,397	1,482	1,881	2,454	2,587	2,886	3,000
Operating Profit	378	560	543	696	897	1,032	1,091
OPM %	21%	27%	22%	22%	26%	26%	27%
Other Income +	41	112	39	10	37	38	52
Interest	3	7	5	36	44	12	6
Depreciation	66	69	73	114	138	171	176
Profit before tax	349	597	505	555	752	887	962
Tax %	22%	25%	24%	26%	26%	26%
Net Profit +	272	449	386	410	553	660	718
EPS in Rs	17.60	28.98	24.93	26.48	35.61	42.37	46.05
Dividend Payout %	31%	28%	33%	34%	34%	37%

Key Metrics

TTM PE Ratio	PB Ratio	Dividend Yield	Sector PE	Sector PB	Sector Div Yld
39.80	8.33	0.84%	36.87	5.82	0.59%

Peers & Comparison

Stock	PE Ratio	PB Ratio	Dividend Yield
J B Chemicals and Pharmaceuticals Ltd	43.35	8.33	0.84%
Sun Pharmaceutical Industries Ltd	39.63	5.98	0.89%
Torrent Pharmaceuticals Ltd	67.04	16.88	0.85%
Cipla Ltd	23.30	3.93	1.05%

Is J B Chemicals & Pharma stock good to buy? (bull case & bear case)

Bull Case:

• The company’s revenue grew from ₹34,842 crore in FY24 to around ₹39,180 crore in FY25, showing about 12% yearly growth.
• Net profit rose from ₹5,526 crore to about ₹6,596 crore, a nearly 20% increase.
• EBITDA improved by about 16%, and the EBITDA margin increased from 26.9% to 27.7%, showing better cost control.
• The company is almost debt-free, with a very low debt-equity ratio of ~0.008:1, meaning low financial risk.
• In Q2 FY26, revenue was around ₹1,085 crore, EBITDA was about ₹319 crore, and profit was almost ₹208 crore.
• Strong brands in heart care, stomach care, and pain relief give a stable income.

Bear Case:

• EBITDA margin was ~27.7% in FY25; rising raw-material or compliance costs could reduce profitability.
• The company relies on exports; currency changes, global demand slowdown, or stricter regulations could hurt revenue.
• Competition in domestic and international markets may affect growth and market share.
• External factors such as a global economic slowdown or regulatory changes can cause unpredictable earnings and stock volatility.

Conclusion

It is a well-known Indian medicine company. It sells medicines in India and other countries, which helps it earn money from different sources. The company is growing steadily, but it still faces challenges like higher costs, rules from the government, changes in currency, and strong competition. Overall, it could be a good choice for people who want to invest for a few years, but those who want quick or very safe returns should be careful.

FAQs